Skip to main content

Table 1 Characteristics of study subjects

From: Inhaled corticosteroid use is associated with increased circulating T regulatory cells in children with asthma

Disease classification No asthma Intermittent Mild persistent Moderate/severe persistent p value
Number of subjects 93 31 15 20  
Age(years) (±SD) 7.6 ± 0.8 7.6 ± 0.5 7.4 ± 0.8 7.4 ± 1.0 0.54
Female 46 (49%) 10 (32%) 6 (40%) 8 (40%) 0.38
Male 47 (51%) 21 (68%) 9 (60%) 12 (60%)  
Caucasian 89 (96%) 29 (94%) 11 (73%) 16 (80) 0.008
African American 3 (3%) 3 (10%) 6 (40%) 6 (30%) <0.0001
American Indian 4 (4%) 0 (0%) 0 (0%) 0 (0%) 0.84
Asian 0 (0%) 1 (3%) 0 (0%) 0 (0%) 0.42
Hispanic or Latino 4 (4 %) 1 (3%) 1 (7%) 0 (0%) 0.83
Spirometry(median [25th, 75th])      
FEV1 1.50 [1.37, 1.72] 1.54 [1.27, 1.66] 1.23 [1.09, 1.63] 1.46 [1.29, 1.83] 0.11
FEV1% pred 103 [95, 109] 103 [89, 113] 90 [85, 101] 102 [94, 107] 0.43
FVC 1.85 [1.64, 2.06] 1.81 [1.60, 2.05] 1.62 [1.31, 1.93] 1.88 [1.51, 2.21] 0.06
FVC% pred 108 [100, 115] 110 [98, 118] 96 [94, 116] 114 [105, 120] 0.19
FEV0.5 1.11 [1.01, 1.30] 1.14 [0.97, 1.29] 0.92 [0.78, 1.18] 1.07 [0.97, 1.21] 0.07
FEF25-75 1.63 [1.23, 1.95] 1.54 [1.03, 1.88] 1.21 [0.98, 1.51] 1.48 [1.25, 1.70] 0.16
PEF 2.98 [2.58, 3.50] 3.20 [2.59, 3.65] 2.46 [2.16, 2.99] 2.66 [2.51, 3.17] 0.07
FEV1/FVC 0.85 [0.79, 0.88] 0.82 [0.77, 0.86] 0.82 [0.81, 0.88] 0.81 [0.77, 0.86] 0.43
FEV0.5/FVC 0.63 [0.58, 0.69] 0.60 [0.55, 0.65] 0.62 [0.56, 0.65] 0.57 [0.55, 0.65] 0.24
Total lgE (median [25th, 75th]) 38 [19, 92] 49 [15, 103] 149 [20, 331] 218 [103, 475] 0.001
Any FEIA 40/91 (44%) 16/29 (55%) 11/15 (73%) 17/20 (85%) 0.003
Aero FEIA 38/91 (42%) 16/29 (55%) 11/15 (73%) 17/20 (85%) 0.002
Perennial aero FEIA 34/91 (37%) 15/29 (52%) 11/15 (73%) 16/20 (80%) 0.001
Seasonal aero FEIA 23/91 (25%) 7/29 (24%) 4/15 (27%) 9/20 (45%) 0.33
  1. FEV1 Forced Expiratory Volume at 1 second, FEV1%pred FEV1 percent predicted, FVC forced vital capacity, FVC%pred, FVC percent predicted; FEV0.5, Forced Expiratory Volume at 0.5 second, FEF25-75, Forced expiratory flow at 25% to 75% of FVC; PEF, peak expiratory flow rate; Aero FEIA, aeroallergen fluoroenzyme immunoassay.